Arcturus Therapeutics Holdings (NasdaqGM:ARCT) – Share price, News & Analysis – Simply Wall St

Stock screener for investors and traders, financial visualizations.

Upgrade your FINVIZ experience

Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.

Learn more about FINVIZ*Elite

Проанализируйте акцию Arcturus Therapeutics
по ключевым показателям


Анализ портфелей 508,074 инвесторов


Сделки инсайдеров и инсайдерский сигнал


Официальная отчетность по сделкам 4 хедж-фондов

Общий обзор

Биржевые данные и финансовые показатели компании


Рейтинг инвестиционной привлекательности компании


Исторические данные и прогнозы по выплатам


Самые свежие новости и общая оценка новостного фона

ARCT Overview

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver and respiratory care diseases.

Price History & Performance

Summary of all time highs, changes and price drops for Arcturus Therapeutics Holdings
Historical stock prices
Current Share Price US$37.43
52 Week High US$129.71
52 Week Low US$24.87
Beta 2.67
1 Month Change -15.41%
3 Month Change -22.05%
1 Year Change -22.22%
3 Year Change 452.07%
5 Year Change n/a
Change since IPO 273.93%

Recent News & Updates

Sep 10

Arcturus Therapeutics Presents Specific Asian COVID-19 Opportunity

The company has a specific opportunity to be a vaccine supplier within Asia and to the world.Re-instated trials are proceeding after disappointment earlier in the year.As a well-capitalised company, there should be no shareholder risk dilution for a couple of years.Company is targeting a range of conditions with its patented mRNA technology, not just COVID-19.The month of August saw a series of promising developments for the company.

Shareholder Returns

ARCT US Biotechs US Market
7D -16.3% -5.5% -0.7%
1Y -22.2% 8.2% 30.0%

Return vs Industry: ARCT underperformed the US Biotechs industry which returned 8.2% over the past year.

Return vs Market: ARCT underperformed the US Market which returned 30% over the past year.

Price Volatility

Is ARCT’s price volatile compared to industry and market?
ARCT volatility
ARCT Average Weekly Movement 9.1%
Biotechs Industry Average Movement 8.6%
Market Average Movement 5.9%
10% most volatile stocks in US Market 15.0%
10% least volatile stocks in US Market 2.2%

Stable Share Price: ARCT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: ARCT’s weekly volatility has decreased from 19% to 9% over the past year.

About the Company

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. Its preclinical drug discovery and development programs include LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene. The company owns LUNAR and nucleic acid technologies that are covered by a patent portfolio of 209 patents and patent applications, issued in the United States and other countries.

Arcturus Therapeutics Holdings Fundamentals Summary

How do Arcturus Therapeutics Holdings’s earnings and revenue compare to its market cap?
ARCT fundamental statistics
Market Cap US$986.67m
Earnings (TTM) -US$196.11m
Revenue (TTM) US$8.80m

Earnings & Revenue

Key profitability statistics from the latest earnings report
ARCT income statement (TTM)
Revenue US$8.80m
Cost of Revenue US$57.85m
Gross Profit -US$49.04m
Expenses US$147.07m
Earnings -US$196.11m

Last Reported Earnings

Sep 30, 2021

Earnings per share (EPS) -7.44
Gross Margin -557.12%
Net Profit Margin -2,227.82%
Debt/Equity Ratio 23.5%

How did ARCT perform over the long term?

See historical performance and comparison

LUNAR®-mediated delivery of RNA into cells

LUNAR® particles associate with the cell membrane of a target cell of interest and quickly enter the cell via endocytosis.

Upon entering the cytosol, the LUNAR® formulations then become trapped in the endosomes.

With increased acidity as the endosome ages, a pH-mediated disruption enables release of the RNA payload following rapid biodegradation of the LUNAR®components.

Once release of the RNA into the cytosol occurs, the translational machinery can interact with the RNA and processing and/or trafficking can then take place to make functional protein.

LUNAR® lipid mediated delivery enables delivery of RNA medicines.

What happened

Shares of Arcturus Therapeutics Holdings (NASDAQ:ARCT) were plunging 53.7% as of 11:16 a.m. EST on Tuesday. The huge decline came after the biotech reported data from an early-stage clinical study of COVID-19 vaccine candidate ARCT-021.

Другие компании сектора Биотехнологии


В таблице представлены только акции, торгующиеся на Санкт-Петербургской бирже, за исключением российских.

  • Business Data for Arcturus Therapeutics: Yahoo Finance Reuters Bloomberg Nasdaq SEC Filings


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.6%.

Top Shareholders

Company Information

Arcturus Therapeutics Holdings Inc.’s employee growth, exchange listings and data sources

Key Information

  • Name: Arcturus Therapeutics Holdings Inc.
  • Ticker: ARCT
  • Exchange: NasdaqGM
  • Founded: 2013
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$986.674m
  • Shares outstanding: 26.36m
  • Website:

Number of Employees


  • Arcturus Therapeutics Holdings Inc.
  • 10628 Science Center Drive
  • Suite 250
  • San Diego
  • California
  • 92121
  • United States


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor’s Capital IQ.
Data Last Updated (UTC time)
Company Analysis 2021/11/12 00:09
End of Day Share Price 2021/11/11 00:00
Earnings 2021/09/30
Annual Earnings 2020/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

( 1 оценка, среднее 5 из 5 )
Загрузка ...